凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
梅花生物(600873)公告正文

梅花生物:2017年第三季度报告

公告日期 2017-10-20
股票简称:梅花生物 股票代码:600873
                        2017 年第三季度报告



公司代码:600873                              公司简称:梅花生物




          梅花生物科技集团股份有限公司
                   2017 年第三季度报告




                              1 / 18
                                                       2017 年第三季度报告




                                                            目录
一、重要提示.........................................................................................................................3

二、公司基本情况.................................................................................................................3

三、重要事项.........................................................................................................................6

四、附录.................................................................................................................................8




                                                                2 / 18
                                             2017 年第三季度报告




     一、 重要提示


     1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,

           不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。

     1.2 公司全体董事出席董事会审议季度报告。

     1.3 公司负责人王爱军、主管会计工作负责人王威及会计机构负责人(会计主管人员)王爱玲保

           证季度报告中财务报表的真实、准确、完整。

     1.4 本公司第三季度报告未经审计。



     二、 公司基本情况


     2.1 主要财务数据
                                                                                  单位:元 币种:人民币
                              本报告期末                    上年度末              本报告期末比上年度末增减(%)
总资产                      17,637,529,352.77                 16,983,012,102.37                             3.85
归属于上市公司股东的净资
                              8,826,878,213.83                 9,064,019,058.49                             -2.62

                            年初至报告期末         上年初至上年报告期末
                                                                                       比上年同期增减(%)
                              (1-9 月)                 (1-9 月)
经营活动产生的现金流量净
                              1,269,717,666.73                 2,370,247,866.04                            -46.43

                            年初至报告期末         上年初至上年报告期末                 比上年同期增减
                              (1-9 月)                 (1-9 月)                         (%)
营业收入                      7,940,373,793.70                 7,927,851,633.42                             0.16
归属于上市公司股东的净利
                               695,327,136.24                   664,526,924.41                              4.63

归属于上市公司股东的扣除
                               543,967,368.46                   566,978,398.74                              -4.06
非经常性损益的净利润
加权平均净资产收益率(%)                  7.53                            7.79              减少 0.26 个百分点
基本每股收益(元/股)                      0.22                            0.21                             4.76
稀释每股收益(元/股)                      0.22                            0.21                          4.76




     非经常性损益项目和金额
     √适用 □不适用



                                                   3 / 18
                                         2017 年第三季度报告


                                                                             单位:元 币种:人民币
                                           本期金额         年初至报告期末金额
                   项目                                                                说明
                                          (7-9 月)           (1-9 月)
非流动资产处置损益                          1,584,107.21           1,766,206.84
越权审批,或无正式批准文件,或偶发性的
税收返还、减免
计入当期损益的政府补助,但与公司正常经
营业务密切相关,符合国家政策规定、按照
                                            8,379,827.15         115,729,657.91
一定标准定额或定量持续享受的政府补助除

计入当期损益的对非金融企业收取的资金占
用费
企业取得子公司、联营企业及合营企业的投
资成本小于取得投资时应享有被投资单位可
辨认净资产公允价值产生的收益
非货币性资产交换损益
委托他人投资或管理资产的损益                                                 -
因不可抗力因素,如遭受自然灾害而计提的
各项资产减值准备
债务重组损益
企业重组费用,如安置职工的支出、整合费
用等
交易价格显失公允的交易产生的超过公允价
值部分的损益
同一控制下企业合并产生的子公司期初至合
并日的当期净损益
与公司正常经营业务无关的或有事项产生的
损益
除同公司正常经营业务相关的有效套期保值
业务外,持有交易性金融资产、交易性金融
负债产生的公允价值变动损益,以及处置交     30,429,230.68          60,500,174.90
易性金融资产、交易性金融负债和可供出售
金融资产取得的投资收益
单独进行减值测试的应收款项减值准备转回
对外委托贷款取得的损益
采用公允价值模式进行后续计量的投资性房
地产公允价值变动产生的损益
根据税收、会计等法律、法规的要求对当期
损益进行一次性调整对当期损益的影响
受托经营取得的托管费收入
除上述各项之外的其他营业外收入和支出        3,905,486.40          -4,816,998.76
其他符合非经常性损益定义的损益项目
少数股东权益影响额(税后)                   -194,866.65            -699,541.20
所得税影响额                                -1,783,341.91        -21,119,731.91
                   合计                    42,320,442.88         151,359,767.78

                                               4 / 18
                                             2017 年第三季度报告




2.2 截止报告期末的股东总数、前十名股东、前十名流通股东(或无限售条件股东)持股情况表
                                                                                                         单位:股
股东总数(户)                                                                                              171,980
                                              前十名股东持股情况
         股东名称           期末持股数      比例    持有有限售条             质押或冻结情况
                                                                                                          股东性质
         (全称)               量          (%)      件股份数量       股份状态               数量
孟庆山                      854,103,033     27.48                 0        质押            546,690,000   境内自然人
胡继军                      248,469,341      7.99                 0        无                            境内自然人
中国证券金融股份有限公
                            139,870,165       4.5                 0        未知                           国有法人

杨维永                       78,810,526      2.54                 0        无                            境内自然人
王爱军                       71,316,274      2.29                 0        质押             46,000,000   境内自然人
梁宇博                       53,668,518      1.73                 0        质押             22,150,000   境内自然人
梅花生物科技集团股份有
限公司-2017 年第一期员      29,007,028      0.93                 0        无                               其他
工持股计划
创金合信基金-浦发银行
-创金合信新活力 1 号分      28,831,607      0.93                 0        未知                             其他
级型资产管理计划
何君                         23,449,758      0.75                 0        无                            境内自然人
中国农业银行股份有限公
司-新华行业轮换灵活配       21,406,913      0.69                 0        未知                             其他
置混合型证券投资基金
                                         前十名无限售条件股东持股情况
                                                                                       股份种类及数量
              股东名称                    持有无限售条件流通股的数量
                                                                                    种类                 数量
孟庆山                                                       854,103,033        人民币普通股             854,103,033
胡继军                                                       248,469,341        人民币普通股             248,469,341
中国证券金融股份有限公司                                     139,870,165        人民币普通股             139,870,165
杨维永                                                        78,810,526        人民币普通股              78,810,526
王爱军                                                        71,316,274        人民币普通股              71,316,274
梁宇博                                                        53,668,518        人民币普通股              53,668,518
梅花生物科技集团股份有限公司-
                                                              29,007,028        人民币普通股              29,007,028
2017 年第一期员工持股计划
创金合信基金-浦发银行-创金合信
                                                              28,831,607        人民币普通股              28,831,607
新活力 1 号分级型资产管理计划
何君                                                          23,449,758        人民币普通股              23,449,758
中国农业银行股份有限公司-新华行
                                                              21,406,913        人民币普通股              21,406,913
业轮换灵活配置混合型证券投资基金
                                          上述股东中,孟庆山、王爱军、何君为一致行动人,其他股东未知其一
上述股东关联关系或一致行动的说明
                                          致行动关系。



                                                    5 / 18
                                                  2017 年第三季度报告



      2.3 截止报告期末的优先股股东总数、前十名优先股股东、前十名优先股无限售条件股东持股情

             况表
      □适用 √不适用



      三、 重要事项


      3.1 公司主要会计报表项目、财务指标重大变动的情况及原因
      √适用 □不适用
      资产负债表项目:                                                           单位:万元
                         本报告期
       项目                          上年度期末        增减额      增减幅度%                   差异说明
                            末
                                                                                  主要系本期为集中收购玉米储备资金增
货币资金              317,353.75     240,441.17       76,912.58         31.99
                                                                                  加融资以及本期销售回款略有增加所致
以公允价值计量且其                                                                主要系本期新增远期结汇业务期末未
变动计入当期损益的        534.57         -             534.57           100.00    结,将其按照公允价值进行计量损益所
金融资产                                                                          致
                                                                                  主要系本期通过银行承兑汇票结算减少
应收票据                 11,217.08   19,791.92        -8,574.84         -43.32
                                                                                  所致
                                                                                  主要系本公司子公司通辽梅花及新疆梅
预付账款                 47,512.52   11,248.33        36,264.20         322.40
                                                                                  花预付玉米款增加所致
                                                                                  主要系本期收回处置原子公司大连汉信
其他应收款               19,583.52   52,381.54       -32,798.02         -62.61
                                                                                  股权款所致
其他流动资产             22,245.62   16,677.84        5,567.78          33.38     主要系本期待抵扣税金增加所致
                                                                                  主要系本期增加对辽宁艾美生物疫苗技
可供出售金融资产         56,391.98   29,451.98        26,940.00         91.47
                                                                                  术集团有限公司股权投资所致
                                                                                  主要系本期增加对通辽德胜生物科技有
长期股权投资              966.61                       966.61           100.00
                                                                                  限公司股权投资,采用权益法计量所致
                                                                                  主要系本期子公司通辽梅花及新疆梅花
在建工程                 66,903.97   13,032.23        53,871.74         413.37
                                                                                  项目投入增加所致
                                                                                  主要系本期子公司通辽梅花工程物资增
工程物资                  484.36       245.32          239.05           97.44
                                                                                  加所致
短期借款              288,173.80     155,591.55      132,582.25         85.21     主要系本期流贷增加所致
以公允价值计量且其
                                                                                  主要系本期新增期权业务,收取期权费
变动计入当期损益的        37.68          -             37.68            100.00
                                                                                  用,按照公允价值计量损益所致
金融负债
应付票据                 7,376.60      10.00          7,366.60      73,666.00     主要系本期增加银行承兑汇票所致
应交税费                 8,268.70    11,950.57        -3,681.87         -30.81    主要系期末应交增值税减少所致
应付利息                 9,662.15     7,290.56        2,371.59          32.53     主要系本期公司债券利息增加所致
应付股利                 8,137.87      966.50         7,171.37          741.99    主要系本公司分红款增加所致
其他流动负债             49,995.34   149,893.99      -99,898.65         -66.65    主要系本期偿还到期短期融资券所致

                                                        6 / 18
                                               2017 年第三季度报告




     利润表项目:                                                           单位:万元
      项目          本报告期        上年同期       增减额      增减幅度%                  差异说明
                                                                            主要系本期车船税、房产税、印花税、土
税金及附加          11,193.67       4,588.23      6,605.44       143.96     地使用税调整至税金及附加列示,同时本
                                                                            期流转税增加,相关税费相应增加
资产减值损失         1,156.35        661.29        495.06        74.86      本期计提坏账准备增加所致
                                                                            主要系本期新增远期结汇业务期末未结,
公允价值变动收益        519.59          -          519.59        100.00
                                                                            将其按照公允价值进行计量损益所致
投资收益             6,036.63       2,049.17      3,987.46       194.59     主要系本期理财收益增加所致
营业外收入          12,797.92       8,587.07      4,210.85       49.04      主要系本期政府补助增加所致
营业外支出           1,530.03        285.68       1,244.35       435.57     主要系本期捐赠支出增加
                                                                            主要系本期子公司通辽梅花利润增加导
所得税费用          12,832.06       8,083.85      4,748.20       58.74      致所得税费用增加以及子公司新疆梅花
                                                                            亏损弥补完毕所得税费用增加所致


     现金流量表项目:                                                                       单位:万元
             项目                本报告期        上年同期       增减额      增减幅度%           差异说明
                                                                                         主要系本期购买原辅材料
经营活动产生的现金流量净额       126,971.77     237,024.79    -110,053.02     -46.43
                                                                                         支付款项增加所致
                                                                                         主要系本期增加对辽宁艾
                                                                                         美生物疫苗技术集团有限
投资活动产生的现金流量净额       -35,875.50      34,390.50    -70,266.00     -204.32
                                                                                         公司股权投资以及本期工
                                                                                         程项目付款增加所致
                                                                                         主要系本期较上期比偿还
筹资活动产生的现金流量净额       -16,795.40     -154,342.45   137,547.06      89.12
                                                                                         借款支出减少所致




     3.2 重要事项进展情况及其影响和解决方案的分析说明
     √适用 □不适用

           1.股份回购进展情况

           公司于2017年6月27日召开的公司第八届董事会第六次会议、2017年7月13日召开的2017年第

     二次临时股东大会审议通过了《关于以集中竞价交易方式回购股份的议案》,具体内容详见公司

     披露在上海证券交易所网站、《上海证券报》及《证券时报》上的相关公告。截止本报告出具日,

     股份回购专户中尚未买入相关股票。

           2.新建项目进展情况

           公司分别于2017年7月11日、2017年7月27日召开了第八届董事会第七次会议和2017年第三次

     临时股东大会,会上审议通过了《关于新建年产40万吨饲料级氨基酸及其配套项目的议案》,具

     体内容详见公司发布在上海证券交易所网站、《上海证券报》及《证券时报》上的公告。2017年8

                                                     7 / 18
                                      2017 年第三季度报告



月10日,公司和白城市人民政府、吉林白城工业园区管委会签署了项目投资合同,新建项目最终

选址地位于吉林省白城工业园区,项目由公司新设的全资子公司吉林梅花氨基酸有限责任公司建

设及生产运营。目前项目进展顺利,项目建设涉及到的立项审批及环评审批正按照既定计划开展。



3.3 报告期内超期未履行完毕的承诺事项
□适用 √不适用



3.4 预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生重大变动的警

    示及原因说明
□适用 √不适用

                                                     公司名称             梅花生物科技集团股份有限公司

                                                    法定代表人                       王爱军

                                                         日期                  2017 年 10 月 19 日




四、 附录


4.1 财务报表
                                    合并资产负债表
                                   2017 年 9 月 30 日
编制单位:梅花生物科技集团股份有限公司

                                                    单位:元 币种:人民币 审计类型:未经审计
                      项目                                期末余额                    年初余额
流动资产:
 货币资金                                                  3,173,537,453.06               2,404,411,667.05
 结算备付金
 拆出资金
 以公允价值计量且其变动计入当期损益的金融资产                   5,345,714.60
 衍生金融资产
 应收票据                                                   112,170,794.59                 197,919,204.39
 应收账款                                                   375,552,072.42                 370,889,184.30
 预付款项                                                   475,125,245.90                 112,483,250.21
 应收保费
 应收分保账款
 应收分保合同准备金


                                                8 / 18
                                      2017 年第三季度报告



 应收利息
 应收股利
 其他应收款                                                195,835,197.49      523,815,364.64
 买入返售金融资产
 存货                                                      700,995,508.88      832,885,913.58
 划分为持有待售的资产
 一年内到期的非流动资产
 其他流动资产                                              222,456,222.55      166,778,404.37
   流动资产合计                                           5,261,018,209.49    4,609,182,988.54
非流动资产:
 发放贷款和垫款
 可供出售金融资产                                          563,919,754.00      294,519,754.00
 持有至到期投资
 长期应收款
 长期股权投资                                                 9,666,143.91
 投资性房地产
 固定资产                                                10,036,379,936.76   10,911,145,082.38
 在建工程                                                  669,039,717.73      130,322,328.06
 工程物资                                                     4,843,638.99        2,453,187.66
 固定资产清理
 生产性生物资产
 油气资产
 无形资产                                                  832,247,179.92      783,523,043.45
 开发支出
 商誉                                                      143,173,700.39      143,173,700.39
 长期待摊费用                                               12,711,480.63       14,556,695.55
 递延所得税资产                                             15,368,976.59       13,905,040.91
 其他非流动资产                                             89,160,614.36       80,230,281.43
   非流动资产合计                                        12,376,511,143.28   12,373,829,113.83
     资产总计                                            17,637,529,352.77   16,983,012,102.37
流动负债:
 短期借款                                                 2,881,738,000.00    1,555,915,457.87
 向中央银行借款
 吸收存款及同业存放
 拆入资金
 以公允价值计量且其变动计入当期损益的金融负债                  376,800.00
 衍生金融负债
 应付票据                                                   73,766,000.00          100,000.00
 应付账款                                                  629,203,128.96      503,748,813.98
 预收款项                                                  407,394,120.27      377,588,983.15
 卖出回购金融资产款
 应付手续费及佣金
 应付职工薪酬                                               87,625,805.12       95,544,866.83


                                                9 / 18
                                     2017 年第三季度报告



 应交税费                                                  82,687,006.69            119,505,692.75
 应付利息                                                  96,621,518.25             72,905,592.51
 应付股利                                                  81,378,696.02               9,665,014.72
 其他应付款                                            321,602,394.03               352,874,712.45
 应付分保账款
 保险合同准备金
 代理买卖证券款
 代理承销证券款
 划分为持有待售的负债
 一年内到期的非流动负债
 其他流动负债                                          499,953,424.64              1,498,939,893.45
   流动负债合计                                       5,162,346,893.98             4,586,789,027.71
非流动负债:
 长期借款                                              300,000,000.00
 应付债券                                             2,989,906,380.72             2,986,745,297.71
 其中:优先股
        永续债
 长期应付款                                                20,000,000.00             20,000,000.00
 长期应付职工薪酬
 专项应付款
 预计负债
 递延收益                                                  89,626,786.40             92,649,984.95
 递延所得税负债
 其他非流动负债
   非流动负债合计                                     3,399,533,167.12             3,099,395,282.66
     负债合计                                         8,561,880,061.10             7,686,184,310.37
所有者权益
 股本                                                 3,108,226,603.00             3,108,226,603.00
 其他权益工具
 其中:优先股
        永续债
 资本公积                                             2,242,451,490.53             2,242,451,490.53
 减:库存股
 其他综合收益
 专项储备
 盈余公积                                              362,759,728.12               362,759,728.12
 一般风险准备
 未分配利润                                           3,113,440,392.18             3,350,581,236.84
 归属于母公司所有者权益合计                           8,826,878,213.83             9,064,019,058.49
 少数股东权益                                          248,771,077.84               232,808,733.51
   所有者权益合计                                     9,075,649,291.67             9,296,827,792.00
     负债和所有者权益总计                            17,637,529,352.77            16,983,012,102.37


法定代表人:王爱军            主管会计工作负责人:王威               会计机构负责人:王爱玲
                                           10 / 18
                                      2017 年第三季度报告



                                   母公司资产负债表
                                   2017 年 9 月 30 日
编制单位:梅花生物科技集团股份有限公司
                                               单位:元 币种:人民币 审计类型:未经审计
                    项目                              期末余额              年初余额
流动资产:
 货币资金                                              1,009,506,341.93        1,071,648,834.22
 以公允价值计量且其变动计入当期损益的金融资产
 衍生金融资产
 应收票据                                                   76,613,009.12       135,333,041.93
 应收账款                                               111,211,746.91          119,324,564.70
 预付款项                                               256,130,566.15           72,896,691.87
 应收利息
 应收股利                                                                      1,000,000,000.00
 其他应收款                                            3,063,786,453.06        3,101,259,495.18
 存货                                                       68,071,800.64        34,455,728.17
 划分为持有待售的资产
 一年内到期的非流动资产
 其他流动资产                                                8,853,597.79        10,604,240.98
   流动资产合计                                        4,594,173,515.60        5,545,522,597.05
非流动资产:
 可供出售金融资产                                       180,919,754.00          260,519,754.00
 持有至到期投资
 长期应收款                                            3,280,741,805.29        3,178,163,222.26
 长期股权投资                                          5,599,575,394.00        5,546,575,394.00
 投资性房地产
 固定资产                                               183,664,370.28          192,774,238.13
 在建工程
 工程物资
 固定资产清理
 生产性生物资产
 油气资产
 无形资产                                               132,233,504.21           70,738,772.90
 开发支出
 商誉
 长期待摊费用                                               12,711,480.63        14,556,695.55
 递延所得税资产                                              5,148,779.82         3,706,449.34
 其他非流动资产
   非流动资产合计                                      9,394,995,088.23        9,267,034,526.18
     资产总计                                         13,989,168,603.83      14,812,557,123.23
流动负债:
 短期借款                                              1,630,000,000.00         830,190,557.87
 以公允价值计量且其变动计入当期损益的金融负债


                                            11 / 18
                                   2017 年第三季度报告



 衍生金融负债
 应付票据                                                85,000,000.00            200,000,000.00
 应付账款                                            648,574,680.92               955,046,073.78
 预收款项                                            260,600,676.86               274,738,822.09
 应付职工薪酬                                            10,320,064.70               9,811,170.43
 应交税费                                                14,825,545.82             30,934,565.80
 应付利息                                                93,210,277.65             69,950,449.18
 应付股利                                                74,463,681.30
 其他应付款                                         1,283,760,965.58             1,029,907,388.62
 划分为持有待售的负债
 一年内到期的非流动负债
 其他流动负债                                        499,953,424.64              1,498,939,893.45
   流动负债合计                                     4,600,709,317.47             4,899,518,921.22
非流动负债:
 长期借款                                            300,000,000.00
 应付债券                                           2,989,906,380.72             2,986,745,297.71
 其中:优先股
        永续债
 长期应付款
 长期应付职工薪酬
 专项应付款
 预计负债
 递延收益
 递延所得税负债
 其他非流动负债
   非流动负债合计                                   3,289,906,380.72             2,986,745,297.71
     负债合计                                       7,890,615,698.19             7,886,264,218.93
所有者权益:
 股本                                               3,108,226,603.00             3,108,226,603.00
 其他权益工具
 其中:优先股
        永续债
 资本公积                                           2,208,701,622.94             2,208,701,622.94
 减:库存股
 其他综合收益
 专项储备
 盈余公积                                            362,759,728.12               362,759,728.12
 未分配利润                                          418,864,951.58              1,246,604,950.24
   所有者权益合计                                   6,098,552,905.64             6,926,292,904.30
     负债和所有者权益总计                          13,989,168,603.83            14,812,557,123.23


法定代表人:王爱军          主管会计工作负责人:王威               会计机构负责人:王爱玲

                                       合并利润表
                                         12 / 18
                                                  2017 年第三季度报告



                                                      2017 年 1-9 月
           编制单位:梅花生物科技集团股份有限公司
                                                              单位:元 币种:人民币 审计类型:未经审计
                                           本期金额                上期金额           年初至报告期       上年年初至报告期
                    项目
                                           (7-9 月)          (7-9 月)           期末金额 (1-9 月) 期末金额(1-9 月)
一、营业总收入                            2,334,579,628.52    2,506,915,324.53        7,940,373,793.70     7,927,851,633.42
其中:营业收入                            2,334,579,628.52    2,506,915,324.53        7,940,373,793.70     7,927,851,633.42
         利息收入
         已赚保费
         手续费及佣金收入
二、营业总成本                            2,287,419,374.06    2,276,546,333.10        7,279,004,858.50     7,271,021,486.82
其中:营业成本                            1,897,558,400.01    1,865,232,342.28        6,000,551,023.81     6,008,825,930.28
         利息支出
         手续费及佣金支出
         退保金
         赔付支出净额
         提取保险合同准备金净额
         保单红利支出
         分保费用
         税金及附加                         31,563,217.24          17,697,337.79        111,936,717.30       45,882,341.09
         销售费用                          176,384,759.79       178,910,142.97          629,600,543.86      565,011,348.92
         管理费用                          107,659,252.47       151,268,674.64          325,291,173.77      459,001,142.96
         财务费用                           74,203,744.55          63,490,616.88        200,061,907.89      185,687,842.48
         资产减值损失                           50,000.00              -52,781.46        11,563,491.87        6,612,881.09
  加:公允价值变动收益(损失以“-”号
                                             3,807,936.60                                 5,195,914.60
填列)
         投资收益(损失以“-”号填列)     30,295,374.59          10,071,721.12         60,366,318.81       20,491,716.71
         其中:对联营企业和合营企业的投
                                              -133,856.09           1,136,624.56           -133,856.09         -941,685.40
资收益
         汇兑收益(损失以“-”号填列)
         其他收益
三、营业利润(亏损以“-”号填列)          81,263,565.65       240,440,712.55          726,931,168.61      677,321,863.31
  加:营业外收入                            14,669,116.89          49,600,959.86        127,979,192.66       85,870,728.75
         其中:非流动资产处置利得            1,881,715.43              66,726.56          2,902,069.40          152,909.64
  减:营业外支出                               799,696.13           1,153,161.33         15,300,326.67        2,856,843.04
         其中:非流动资产处置损失              297,608.22             490,031.54          1,135,862.56        1,518,584.88
四、利润总额(亏损总额以“-”号填列)      95,132,986.41       288,888,511.08          839,610,034.60      760,335,749.02
  减:所得税费用                            16,498,800.18          23,596,433.28        128,320,554.03       80,838,544.50
五、净利润(净亏损以“-”号填列)          78,634,186.23       265,292,077.80          711,289,480.57      679,497,204.52
  归属于母公司所有者的净利润                74,884,081.07       260,431,050.69          695,327,136.24      664,526,924.41
  少数股东损益                               3,750,105.16           4,861,027.11         15,962,344.33       14,970,280.11
六、其他综合收益的税后净额
归属母公司所有者的其他综合收益的税


                                                         13 / 18
                                                 2017 年第三季度报告



后净额
       (一)以后不能重分类进损益的其他
综合收益
         1.重新计量设定受益计划净负债
或净资产的变动
         2.权益法下在被投资单位不能重
分类进损益的其他综合收益中享有的份

       (二)以后将重分类进损益的其他综
合收益
         1.权益法下在被投资单位以后将
重分类进损益的其他综合收益中享有的
份额
         2.可供出售金融资产公允价值变
动损益
         3.持有至到期投资重分类为可供
出售金融资产损益
         4.现金流量套期损益的有效部分
         5.外币财务报表折算差额
         6.其他
归属于少数股东的其他综合收益的税后
净额
七、综合收益总额                           78,634,186.23       265,292,077.80            711,289,480.57          679,497,204.52
  归属于母公司所有者的综合收益总额         74,884,081.07       260,431,050.69            695,327,136.24          664,526,924.41
  归属于少数股东的综合收益总额              3,750,105.16            4,861,027.11           15,962,344.33           14,970,280.11
八、每股收益:
  (一)基本每股收益(元/股)                         0.02                      0.08                  0.22                      0.21
  (二)稀释每股收益(元/股)                         0.02                      0.08                  0.22                      0.21


           本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:0 元, 上期被合并方实现的
           净利润为: 0 元。
           法定代表人:王爱军        主管会计工作负责人:王威        会计机构负责人:王爱玲



                                               母公司利润表
                                               2017 年 1-9 月
           编制单位:梅花生物科技集团股份有限公司
                                                      单位:元 币种:人民币 审计类型:未经审计
                                                                                     年初至报告期期     上年年初至报告
                                             本期金额              上期金额
                          项目                                                           末金额             期期末金额
                                            (7-9 月)         (7-9 月)
                                                                                       (1-9 月)            (1-9 月)
           一、营业收入                   1,398,648,649.36   1,565,201,708.99        4,922,612,594.54      5,012,726,516.02
             减:营业成本                 1,219,180,500.16   1,414,081,551.32        4,325,254,305.43      4,526,710,353.59
                  税金及附加                 3,468,255.98            337,459.21        10,719,412.20          3,394,180.16

                                                         14 / 18
                                           2017 年第三季度报告



         销售费用                     110,306,376.95    111,041,646.05      406,483,884.92   346,785,724.10
         管理费用                      32,957,833.71        41,588,687.62    96,618,335.67   116,654,249.92
         财务费用                       3,628,072.74         1,310,642.71     9,621,507.04      -665,613.47
         资产减值损失                                                         9,615,536.51     5,169,432.98
  加:公允价值变动收益(损失以
“-”号填列)
         投资收益(损失以“-”号填
                                       14,255,352.38         3,027,440.67    30,538,132.81     6,955,748.97
列)
         其中:对联营企业和合营企
                                                             1,136,624.56                       -941,685.40
业的投资收益
         其他收益
二、营业利润(亏损以“-”号填列)     43,362,962.20          -130,837.25    94,837,745.58    21,633,937.71
  加:营业外收入                         909,773.60         14,826,820.07    13,149,246.95    16,434,506.91
         其中:非流动资产处置利得                                                                  3,659.54
  减:营业外支出                           20,158.97           70,781.75       625,647.06       103,605.00
         其中:非流动资产处置损失           4,559.97             1,166.49        22,413.81         9,451.56
三、利润总额(亏损总额以“-”号
                                       44,252,576.83        14,625,201.07   107,361,345.47    37,964,839.62
填列)
     减:所得税费用                     3,982,779.69                          2,633,363.23      -775,414.94
四、净利润(净亏损以“-”号填列)     40,269,797.14        14,625,201.07   104,727,982.24    38,740,254.56
五、其他综合收益的税后净额
  (一)以后不能重分类进损益的
其他综合收益
     1.重新计量设定受益计划净负
债或净资产的变动
     2.权益法下在被投资单位不能
重分类进损益的其他综合收益中享
有的份额
  (二)以后将重分类进损益的其
他综合收益
     1.权益法下在被投资单位以后
将重分类进损益的其他综合收益中
享有的份额
     2.可供出售金融资产公允价值
变动损益
     3.持有至到期投资重分类为可
供出售金融资产损益
     4.现金流量套期损益的有效部

     5.外币财务报表折算差额
     6.其他
六、综合收益总额                       40,269,797.14        14,625,201.07   104,727,982.24    38,740,254.56
七、每股收益:
     (一)基本每股收益(元/股)

                                                  15 / 18
                                        2017 年第三季度报告



   (二)稀释每股收益(元/股)


法定代表人:王爱军               主管会计工作负责人:王威               会计机构负责人:王爱玲

                                  合并现金流量表
                                    2017 年 1-9 月
编制单位:梅花生物科技集团股份有限公司
                                           单位:元 币种:人民币 审计类型:未经审计
                     项目                      年初至报告期期末金额           上年年初至报告期期末金额
                                                     (1-9 月)                      (1-9 月)
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金                          8,123,898,133.89                7,871,741,278.94
  客户存款和同业存放款项净增加额
  向中央银行借款净增加额
  向其他金融机构拆入资金净增加额
  收到原保险合同保费取得的现金
  收到再保险业务现金净额
  保户储金及投资款净增加额
  处置以公允价值计量且其变动计入当期损益
的金融资产净增加额
  收取利息、手续费及佣金的现金
  拆入资金净增加额
  回购业务资金净增加额
  收到的税费返还                                              24,022,514.52                57,579,785.79
  收到其他与经营活动有关的现金                            336,379,548.59                  196,484,054.20
    经营活动现金流入小计                                8,484,300,197.00                8,125,805,118.93
  购买商品、接受劳务支付的现金                          5,051,555,208.56                3,876,717,905.58
  客户贷款及垫款净增加额
  存放中央银行和同业款项净增加额
  支付原保险合同赔付款项的现金
  支付利息、手续费及佣金的现金
  支付保单红利的现金
  支付给职工以及为职工支付的现金                          564,860,436.66                  525,258,123.43
  支付的各项税费                                          574,689,994.22                  508,734,258.62
  支付其他与经营活动有关的现金                          1,023,476,890.83                  844,846,965.26
    经营活动现金流出小计                                7,214,582,530.27                5,755,557,252.89
      经营活动产生的现金流量净额                        1,269,717,666.73                2,370,247,866.04
二、投资活动产生的现金流量:
  收回投资收到的现金                                          96,600,000.00               566,900,000.00
  取得投资收益收到的现金                                      60,477,001.11                21,715,435.10
  处置固定资产、无形资产和其他长期资产收回
                                                                151,600.00                    407,644.64
的现金净额
  处置子公司及其他营业单位收到的现金净额                  300,000,000.00
  收到其他与投资活动有关的现金
                                              16 / 18
                                        2017 年第三季度报告



    投资活动现金流入小计                                  457,228,601.11                  589,023,079.74
  购建固定资产、无形资产和其他长期资产支付
                                                          414,526,826.17                  187,700,588.76
的现金
  投资支付的现金                                          401,456,737.49                   57,417,473.00
  质押贷款净增加额
  取得子公司及其他营业单位支付的现金净额
  支付其他与投资活动有关的现金
    投资活动现金流出小计                                  815,983,563.66                  245,118,061.76
      投资活动产生的现金流量净额                         -358,754,962.55                  343,905,017.98
三、筹资活动产生的现金流量:
  吸收投资收到的现金
  其中:子公司吸收少数股东投资收到的现金
  取得借款收到的现金                                    2,875,727,000.00                2,431,293,828.35
  发行债券收到的现金
  收到其他与筹资活动有关的现金                                                            948,045,471.98
    筹资活动现金流入小计                                2,875,727,000.00                3,379,339,300.33
  偿还债务支付的现金                                    1,990,316,000.00                4,058,226,617.50
  分配股利、利润或偿付利息支付的现金                    1,017,098,555.92                  482,894,514.94
  其中:子公司支付给少数股东的股利、利润
  支付其他与筹资活动有关的现金                                36,266,395.89               381,642,691.43
    筹资活动现金流出小计                                3,043,680,951.81                4,922,763,823.87
      筹资活动产生的现金流量净额                         -167,953,951.81                -1,543,424,523.54
四、汇率变动对现金及现金等价物的影响                      -10,149,362.25                    7,205,937.43
五、现金及现金等价物净增加额                              732,859,390.12                1,177,934,297.91
  加:期初现金及现金等价物余额                          2,402,880,986.97                  245,643,678.36
六、期末现金及现金等价物余额                            3,135,740,377.09                1,423,577,976.27


法定代表人:王爱军               主管会计工作负责人:王威               会计机构负责人:王爱玲

                                  母公司现金流量表
                                    2017 年 1-9 月
编制单位:梅花生物科技集团股份有限公司
                                           单位:元 币种:人民币 审计类型:未经审计
                     项目                      年初至报告期期末金额           上年年初至报告期期末金额
                                                     (1-9 月)                      (1-9 月)
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金                          5,085,857,222.10                4,753,547,661.71
  收到的税费返还
  收到其他与经营活动有关的现金                          2,804,182,282.20                3,026,507,961.43
    经营活动现金流入小计                                7,890,039,504.30                7,780,055,623.14
  购买商品、接受劳务支付的现金                          4,571,199,484.36                3,987,350,380.27
  支付给职工以及为职工支付的现金                              56,974,710.70                40,481,298.23
  支付的各项税费                                              72,021,174.57                59,125,077.39
  支付其他与经营活动有关的现金                          3,699,938,121.40                3,047,556,603.07
                                              17 / 18
                                        2017 年第三季度报告



    经营活动现金流出小计                                8,400,133,491.03              7,134,513,358.96
  经营活动产生的现金流量净额                             -510,093,986.73               645,542,264.18
二、投资活动产生的现金流量:
  收回投资收到的现金                                          79,600,000.00            195,200,000.00
  取得投资收益收到的现金                                1,030,543,205.77               309,122,177.94
  处置固定资产、无形资产和其他长期资产收回
                                                                                           210,000.00
的现金净额
  处置子公司及其他营业单位收到的现金净额
  收到其他与投资活动有关的现金
    投资活动现金流入小计                                1,110,143,205.77               504,532,177.94
  购建固定资产、无形资产和其他长期资产支付
                                                              29,144,361.34             27,928,097.53
的现金
  投资支付的现金                                              53,000,000.00             73,969,972.76
  取得子公司及其他营业单位支付的现金净额
  支付其他与投资活动有关的现金
    投资活动现金流出小计                                      82,144,361.34            101,898,070.29
      投资活动产生的现金流量净额                        1,027,998,844.43               402,634,107.65
三、筹资活动产生的现金流量:
  吸收投资收到的现金
  取得借款收到的现金                                    1,230,000,000.00              1,689,000,000.00
  发行债券收到的现金
  收到其他与筹资活动有关的现金                            289,007,484.20              2,357,678,066.67
    筹资活动现金流入小计                                1,519,007,484.20              4,046,678,066.67
  偿还债务支付的现金                                    1,100,000,000.00              2,789,000,000.00
  分配股利、利润或偿付利息支付的现金                      999,054,832.22               463,009,180.78
  支付其他与筹资活动有关的现金                                26,000,000.00           1,434,900,000.00
    筹资活动现金流出小计                                2,125,054,832.22              4,686,909,180.78
      筹资活动产生的现金流量净额                         -606,047,348.02              -640,231,114.11
四、汇率变动对现金及现金等价物的影响                                  -1.97                       1.22
五、现金及现金等价物净增加额                              -88,142,492.29               407,945,258.94
  加:期初现金及现金等价物余额                          1,071,648,834.22                77,736,675.89
六、期末现金及现金等价物余额                              983,506,341.93               485,681,934.83


法定代表人:王爱军               主管会计工作负责人:王威               会计机构负责人:王爱玲



4.2 审计报告
□适用 √不适用




                                              18 / 18
数据加载中...
prevnext
手机查看股票